First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 123 participants.

Also called NCT01960504

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 123 participants (enrolled count) (from the registry)
Sponsor
  • Biotronik AG Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01960504
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium, Brazil, Denmark, Germany, Netherlands, Singapore, Spain, Switzerland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01960504. Allocation not applicable; no masking; primary purpose treatment. Start 2013-10 (actual); primary completion 2015-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)
Acronym
BIOSOLVE-II
Condition
Coronary Artery Stenosis
Intervention (Device)
Percutaneous Coronary Intervention (DREAMS) stenting
Lead sponsor
Biotronik AG (class: industry)

Record details

Record id
cardio:ct-nct01960504
Content hash
8203ae27c986d5461b46a455e7c079f1f0a2e425ea706a2e25f3862e76a94328